155 related articles for article (PubMed ID: 26129821)
1. Histone deacetylase inhibition impairs normal intestinal cell proliferation and promotes specific gene expression.
Roostaee A; Guezguez A; Beauséjour M; Simoneau A; Vachon PH; Levy E; Beaulieu JF
J Cell Biochem; 2015 Nov; 116(11):2695-708. PubMed ID: 26129821
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
3. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.
Duncan HF; Smith AJ; Fleming GJ; Partridge NC; Shimizu E; Moran GP; Cooper PR
J Cell Physiol; 2016 Apr; 231(4):798-816. PubMed ID: 26264761
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
5. Identification of an epigenetic signature of early mouse liver regeneration that is disrupted by Zn-HDAC inhibition.
Huang J; Schriefer AE; Yang W; Cliften PF; Rudnick DA
Epigenetics; 2014 Nov; 9(11):1521-31. PubMed ID: 25482284
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA.
Cheng HT; Hung WC
Oncol Rep; 2013 Aug; 30(2):961-7. PubMed ID: 23754070
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Cheng HT; Hung WC
Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors trichostatin A and vorinostat inhibit TGFβ2-induced lens epithelial-to-mesenchymal cell transition.
Xie L; Santhoshkumar P; Reneker LW; Sharma KK
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):4731-40. PubMed ID: 24994865
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.
Faraco G; Pancani T; Formentini L; Mascagni P; Fossati G; Leoni F; Moroni F; Chiarugi A
Mol Pharmacol; 2006 Dec; 70(6):1876-84. PubMed ID: 16946032
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition regulates miR-449a levels in skeletal muscle cells.
Poddar S; Kesharwani D; Datta M
Epigenetics; 2016 Aug; 11(8):579-87. PubMed ID: 27184529
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
14. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells.
Wu Q; Xu W; Cao L; Li X; He T; Wu Z; Li W
J Proteome Res; 2013 Sep; 12(9):4064-73. PubMed ID: 23909948
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
Koppel I; Timmusk T
Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.
Shi ZJ; Ouyang DY; Zhu JS; Xu LH; He XH
Int Immunopharmacol; 2012 Apr; 12(4):580-7. PubMed ID: 22369900
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase.
Ling D; Marshall GM; Liu PY; Xu N; Nelson CA; Iismaa SE; Liu T
Eur J Cancer; 2012 Nov; 48(17):3278-87. PubMed ID: 22459762
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid enhances odontoblast differentiation.
Kwon A; Park HJ; Baek K; Lee HL; Park JC; Woo KM; Ryoo HM; Baek JH
J Dent Res; 2012 May; 91(5):506-12. PubMed ID: 22447851
[TBL] [Abstract][Full Text] [Related]
20. SAHA, an HDAC inhibitor, attenuates antibody-mediated allograft rejection.
Zhang X; Guo M; Kang Y; Liu F; Zheng X; Han S; Fu S; Hong S; Ding G; Wang L; Wang QX
Transplantation; 2013 Sep; 96(6):529-37. PubMed ID: 23912176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
